Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation - 1 Apr 2022

FitzMaurice Thomas Simon, Nazareth Dilip, Iyer Kapil, Walshaw Martin, Al-Aloul Mohamed

Abstract excerpt

The triple-combination cystic fibrosis transmembrane conductance regulator modulator elexacaftor/- tezacaftor/ivacaftor is known to improve lung function and have extrapulmonary benefits in people with cystic fibrosis. However, there is limited evidence for its use in patients with cystic fibrosis after lung transplant, where the donor lung expresses normal levels of the cystic fibrosis transmembrane conductance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chloride Channel Agonists

Share to Indoles

Share to Pyrazoles

Share to Pyridines

Share to Pyrrolidines

Share to Quinolones

Source

Identifiers

PMID: 35297329
DOI: 10.6002/ect.2021.0468

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.PMID 35297329Read ↗

Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.Semantic proximity Read ↗

The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.Semantic proximity Read ↗

Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.Semantic proximity Read ↗

The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France.Semantic proximity Read ↗

Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?Semantic proximity Read ↗

Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.Semantic proximity Read ↗

Use of CFTR Modulators for Cystic Fibrosis in a Patient with Liver Transplant and ESRD on Hemodialysis.Semantic proximity Read ↗

Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.Semantic proximity Read ↗

Changes in liver biochemistry and tacrolimus levels following the introduction of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and liver transplant.Semantic proximity Read ↗

A new triple combination cystic fibrosis transmembrane regulator modulator.Semantic proximity Read ↗

Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.Semantic proximity Read ↗

Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.